Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02208063 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
A Phase 3 study, sponsored by Cumberland Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT02208063 is a Phase 3 study that was terminated before completion, run by Cumberland Pharmaceuticals. The registered enrollment target is 121 participants.
The verdict
NCT02208063, a Phase 3 study, was terminated before completion, sponsored by Cumberland Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).
Interventions
- DRUG Vancomycin
- DRUG Cefazolin
- DRUG Daptomycin
- DRUG Telavancin
- DRUG Synthetic penicillin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-04-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02208063
The ClinicalTrials.gov registry entry for NCT02208063 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vancomycin is the first listed.
NCT02208063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02208063 about?
NCT02208063 is a clinical study titled "A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial". This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA ri...
What is the current status of trial NCT02208063?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2014-12. Estimated completion is 2018-04-12.
What interventions are being tested in trial NCT02208063?
The interventions under investigation include: Vancomycin (DRUG), Cefazolin (DRUG), Daptomycin (DRUG), Telavancin (DRUG), Synthetic penicillin (DRUG).
Who is sponsoring clinical trial NCT02208063?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.